Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
6,640.00
0.00 (0.00%)
Oct 5, 2025, 3:49 PM IDT
Market Cap74.99B
Revenue (ttm)56.02B
Net Income (ttm)-528.98M
Shares Outn/a
EPS (ttm)-0.47
PE Ration/a
Forward PE7.73
Dividendn/a
Ex-Dividend Daten/a
Volume1,186,658
Average Volume1,417,796
Open6,620.00
Previous Close6,640.00
Day's Range6,575.00 - 6,644.00
52-Week Range4,865.00 - 8,431.00
Beta0.71
RSI63.49
Earnings DateNov 5, 2025

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside

Teva Pharmaceutical Industries is regaining investor interest as restructuring efforts drive margin improvements. Read why TEVA stock is a Buy.

23 hours ago - Seeking Alpha

FDA Initiative May Impact Teva's (TEVA) Generic Drug Endeavors

FDA Initiative May Impact Teva's (TEVA) Generic Drug Endeavors

4 days ago - GuruFocus

JP Morgan Maintains Overweight Rating on TEVA, Price Target Raised to $26 | TEVA Stock News

JP Morgan Maintains Overweight Rating on TEVA, Price Target Raised to $26 | TEVA Stock News

4 days ago - GuruFocus

Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus

Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus (NYSE: TEVA). And retail traders should know. We noticed this today when the trades showed up on public...

7 days ago - Benzinga

Notable ETF Inflow Detected - IXUS, PDD, NU, TEVA

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI Total International Stock ETF (Symbol: IXUS) where w...

7 days ago - Nasdaq

Teva Releases Q3 2025 Aide Memoire

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its...

12 days ago - GlobeNewsWire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial re...

12 days ago - GlobeNewsWire

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Wall Street is slowly beginning to understand that Teva Pharmaceutical Industries Limited is rapidly transforming from a generic medication supplier into one of the key players in the CNS treatment ma...

12 days ago - Seeking Alpha

November 7th Options Now Available For Teva Pharmaceutical Industries (TEVA)

Investors in Teva Pharmaceutical Industries Ltd (Symbol: TEVA) saw new options begin trading today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

12 days ago - Nasdaq

TEVA's Price Target Raised to $26 by UBS, Rating Maintained at 'Buy' | TEVA Stock News

TEVA's Price Target Raised to $26 by UBS, Rating Maintained at 'Buy' | TEVA Stock News

13 days ago - GuruFocus

Is Teva Pharmaceutical Indus Gaining or Losing Market Support?

Teva Pharmaceutical Indus's (NYSE: TEVA) short interest as a percent of float has risen 9.14% since its last report. According to exchange reported data, there are now 50.51 million shares sold short...

13 days ago - Benzinga

Bausch Health (BHC) and Teva Accused of Antitrust Violations Over Xifaxan

Bausch Health (BHC) and Teva Accused of Antitrust Violations Over Xifaxan

14 days ago - GuruFocus

Bausch, Teva face lawsuit for delay in generic version of Xifaxan

Bausch Health and Teva face an antitrust lawsuit for allegedly delaying generic Xifaxan. Read more here.

14 days ago - Seeking Alpha

Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?

ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.

14 days ago - Nasdaq

Teva (TEVA) Highlights Schizophrenia Drug Portfolio at Annual Meeting

Teva (TEVA) Highlights Schizophrenia Drug Portfolio at Annual Meeting

16 days ago - GuruFocus

Teva (TEVA) Reports Positive Feedback on AUSTEDO XR from Patient Survey

Teva (TEVA) Reports Positive Feedback on AUSTEDO XR from Patient Survey

16 days ago - GuruFocus

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the pres...

17 days ago - GlobeNewsWire

HEFA, EFA, TEVA, MNDY: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Currency Hedged MSCI EAFE ETF (Symbol: HEFA) where we have det...

18 days ago - Nasdaq

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place fr...

20 days ago - Business Wire

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 202...

21 days ago - GlobeNewsWire

Insider Buying: David Mcavoy Acquires Shares in Teva Pharmaceutical Industries Ltd (TEVA)

Insider Buying: David Mcavoy Acquires Shares in Teva Pharmaceutical Industries Ltd (TEVA)

4 weeks ago - GuruFocus